Male androgen deficiency syndrome screening questionnaire: A simplified instrument to identify testosterone-deficient men

Journal of Men's Health

Volumn 11, Issue 1, 2014, Pages 28-37

  Stone, Nelson N ^a   Miner, Martin ^b   Poage, Wendy L ^c   Patel, Aditi ^d   Crawford, E David ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c Prostate Conditions Education Council   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Diabetes; Hypogonadism; Obesity; Quality of life; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AFRICAN AMERICAN; AGED; ANDROGEN DEFICIENCY; ARTICLE; ASIAN; CAUCASIAN; CLINICAL EVALUATION; ERECTILE DYSFUNCTION; EXERCISE; GROUPS BY AGE; HEART DISEASE; HEART INFARCTION; HISPANIC; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MALE ANDROGEN DEFICIENCY SYNDROME QUESTIONNAIRE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SCREENING; TESTOSTERONE BLOOD LEVEL;

EID: 84978086908     PISSN: 18756867     EISSN: 18756859     Source Type: Journal    
DOI: 10.1089/jomh.2013.0027     Document Type: Article

References (20)

1. Svartberg J, von Mühlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromsø study. Eur J Epidemiol 2004;19: 657-663.
2. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490-494.
3. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82:682-685.
4. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
5. Kratzik C, Heinemann LAJ, Saad F, et al. Composite screener for androgen deficiency related to the Aging Males' Symptoms scale. Aging Male 2005;8:157-161.
6. Stone NN, Crawford ED, DeAntoni EP, and the Prostate Cancer Education Council. Screening for prostate cancer by digital rectal exam and prostate-specific antigen: Results of prostate cancer awareness week, 1989-1992. Urology 1994;44:18-25.
7. Rosen RC, Araujo AB, Connor MK, et al. The NERI Hypogonadism Screener: Psychometric validation in male patients and controls. Clin Endocrinol (Oxf) 2011;74:248-256.
8. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60: 762-769.
9. Araujo A, O'Donnell A, Brambilla D, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metabol 2004;89:5920-5926.
10. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86: 724-731.
11. Ryan GJ, Jobe LJ. Age-related androgen deficiency and type 2 diabetes. J Pharm Pract 2011;24:316-322.
12. Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol 2013;78:330-337.
13. Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011;96:2643-2651.
14. Mazur A. The age-testosterone relationship in black, white, and Mexican-American men, and reasons for ethnic differences. Aging Male 2009;12:66-76.
15. Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 2006;91:4326-4334.
16. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004;7:211-218.
17. Ho CC, Tong SF, Low WY, et al. A randomized, doubleblind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012;110:260-265.
18. Caminiti G, Volterrani M, Iellamo F, et al. Effect of longacting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-927.
19. Behre HM, Tammela TL, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15: 198-207.
20. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97:2050-2058.